Back to Agenda
Session 4: Risk Management And Communication For Vaccines. Biotherapeutics Impact Of Covid-19 Pandemic
Session Chair(s)
Francoise Sillan, MD
EU1 UK QPPV, Ipsen, France
Guy Demol
EU QPPV, MSD, Belgium
Effective communication about safety of vaccines and vaccination is critical: perceptions of harm may persist despite evidence that a serious adverse event is not related to the vaccination and communicating about vaccine safety to multiple audiences (e.g. healthcare providers, patients and parents) is complex.
The ongoing threat to global health from COVID-19 poses critical challenges with an abundance of information and misinformation on the disease and on vaccination. The stakeholder’s perceptions regarding vaccine safety has an impact on coverage rates. This session will explore these different challenges from regulator, industry and academic perspectives.
Speaker(s)
Regulators Experience with Vaccines Safety Assessment
Emil Andrei Cochino, MD, MHS
Scientific Senior Specialist (Risk Management), European Medicines Agency, Netherlands
Development of Vaccines and Biotherapeutics: Addressing the Emergency – Experience from Industry
Patrick M. Caubel, MD, PhD, MBA
Chief Safety Officer, Pfizer Inc, United States
Communication of Benefit Risks to the Public: Impact of Media
Frederic Bouder, PhD
Professor in Risk Management, University of Stavanger, Norway
Have an account?